CJC 1295 with DAC vs Without DAC and Which One You Should Actually Use

The reason most people choose CJC 1295 with DAC is simple math. One injection per week beats multiple injections per week, and that sounds like a straight upgrade with no downside. But DAC does not just change how often you inject. It changes what your pituitary does between injections, and that is the part that determines whether the compound works the way you think it does.

To understand why, you need the full picture first.

Your body releases growth hormone in pulses. Not a steady stream, but sharp spikes that fire several times throughout the day, with the largest ones happening during deep sleep. Between those spikes, growth hormone levels drop back down close to zero, and those low valleys are not wasted time. They are part of the system. The receptors that respond to growth hormone need that downtime to stay sensitive and ready to fire again. The rhythm is the mechanism.

CJC 1295 is something called a GHRH analog, which is a compound that mimics growth hormone releasing hormone, the signal your hypothalamus sends to your pituitary to trigger a growth hormone pulse. When you inject CJC 1295 without DAC, it acts like a louder version of that signal. It hits the pituitary, triggers a pulse, and then clears out in about 30 minutes. Your pituitary fires a bigger spike, and then your natural pattern resumes. The valleys come back. The rhythm stays intact.

DAC stands for drug affinity complex, and it is a modification added to the CJC 1295 molecule that causes it to bind to a protein in your blood called albumin. Albumin is essentially a carrier protein that shuttles things around your bloodstream, and when CJC 1295 binds to it, the compound stops being cleared and just keeps circulating. That extends the half life from roughly 30 minutes all the way out to somewhere between 5.8 and 8.1 days depending on the individual.

So one injection lasts a week. That is the appeal.

But here is what actually happens inside that week. Because the compound is still active, your pituitary is receiving a continuous GHRH signal the entire time. A study by Ionescu and Frohman published in 2006 looked at this directly, and they found that the pulsatile spikes do still happen with CJC 1295 DAC, which sounds reassuring at first. The pulses are not eliminated. But the baseline between those pulses, what researchers call the trough level, was elevated 7.5 times above normal. The valleys fill in. Instead of rising sharply and dropping back to near zero, growth hormone levels rise and then only drop back to a floor that is already 7.5 times higher than where it should be. The pattern stops looking like pulses and starts looking like a flat elevation with ripples on top.

That distinction matters more than it sounds, because the body responds to growth hormone patterns differently depending on the shape of that pattern.

A study by Surya and colleagues published in 2009 tested this directly in humans by comparing pulsatile growth hormone delivery against continuous growth hormone delivery and measuring fat breakdown, which is one of the primary benefits people are chasing with these compounds. Pulsatile delivery raised lipolysis from a baseline of 4.1 up to 7.1, which is nearly double. Continuous delivery moved it from 4.1 to only 4.8, a difference that was not statistically significant from doing nothing. Same total growth hormone exposure, completely different outcome based entirely on the pattern of delivery.

The reason for that difference comes down to receptor behavior. There is a mechanism called downregulation, which is when a receptor reduces its own sensitivity in response to sustained stimulation. Think of it like standing next to a loud speaker. After a while your ears stop hearing it as loud because your brain turns down the gain to protect itself. Receptors do the same thing. A study by Aleppo and colleagues found that continuous GHRH exposure for just four hours reduced the expression of GHRH receptors on pituitary cells to between 49 and 54 percent of their starting level. That is roughly half the receptors gone in four hours, driven by a cAMP-mediated process that scales with how high the dose is. With DAC keeping the signal running for days at a time, that same downregulation pressure does not let up.

This is why the pulsatile pattern is not just a feature of natural physiology. It is what keeps the system responsive.

Now here is where the logic of choosing DAC starts to collapse on itself. If you are going to run a continuous elevation of growth hormone rather than a pulsatile one, you are not using a secretagogue the way a secretagogue is meant to be used. The entire point of choosing a GHRH analog over injectable growth hormone is that it works with your body's own rhythm rather than overriding it. Continuous elevation is exactly what exogenous growth hormone does. And if that is the goal, injectable growth hormone at least comes with precise dosing and decades of clinical data on its effects and risks. CJC 1295 with DAC gives you the continuous elevation pattern without the dosing precision, and without the research depth. You end up in a middle position where you have lost the pulsatile advantage of the secretagogue but have not gained the control that comes with using growth hormone directly.

CJC 1295 without DAC keeps the valleys. It triggers the spike, clears out, and lets your pituitary return to its baseline before the next dose. Multiple injections per week is not a downside of the short-acting version. It is how the short-acting version stays effective.

The inconvenience is the mechanism.

---

References

1. Surya S et al. The pattern of growth hormone delivery to peripheral tissues determines insulin-like growth factor-1 and lipolytic responses in obese subjects. J Clin Endocrinol Metab. 2009;948:2828-2834 — Pulsatile GH nearly doubled lipolysis 7.1 vs 4.1 baseline, continuous was not significantly different from baseline 4.8 vs 4.1. Source
2. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295, a long-acting GHRH analog. J Clin Endocrinol Metab. 2006;9112:4792-4797 — CJC-1295 DAC preserved pulse frequency and magnitude but elevated basal trough GH 7.5-fold. Source
3. Teichman SL et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;913:799-805 — CJC-1295 DAC half-life 5.8-8.1 days due to albumin binding. Source
4. Aleppo G et al. Homologous down-regulation of growth hormone-releasing hormone receptor messenger ribonucleic acid levels. Endocrinology. 1997;1383:1058-1065 — Continuous GHRH exposure for 4 hours reduced GHRH receptor mRNA to 49-54% of baseline, dose-dependent and cAMP-mediated. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness